Propanamide, 2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-, (2S)-, methanesulfonate (1:1)
| Title | Journal |
|---|---|
| Disposition and metabolism of safinamide, a novel drug for Parkinson's disease, in healthy male volunteers. | Pharmacology 20130101 |
| The effect of safinamide, a novel drug for Parkinson's disease, on pressor response to oral tyramine: a randomized, double-blind, clinical trial. | Clinical pharmacology and therapeutics 20121001 |
| A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients. | Movement disorders : official journal of the Movement Disorder Society 20120101 |
| Pressor response to oral tyramine during co-administration with safinamide in healthy volunteers. | Naunyn-Schmiedeberg's archives of pharmacology 20111201 |
| A validated chiral liquid chromatographic method for the enantiomeric separation of safinamide mesilate, a new anti-Parkinson drug. | Journal of pharmaceutical and biomedical analysis 20110428 |
| Safinamide in the treatment of Parkinson's disease. | Expert opinion on pharmacotherapy 20100901 |
| Two polymorphs of safinamide, a selective and reversible inhibitor of monoamine oxidase B. | Acta crystallographica. Section C, Crystal structure communications 20100601 |
| Merging the structural motifs of functionalized amino acids and alpha-aminoamides: compounds with significant anticonvulsant activities. | Journal of medicinal chemistry 20100513 |
| An expert opinion on safinamide in Parkinson's disease. | Expert opinion on investigational drugs 20080701 |
| Monoamine oxidase-B inhibition in the treatment of Parkinson's disease. | Pharmacotherapy 20071201 |
| Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. | Journal of medicinal chemistry 20071115 |
| Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase. | Journal of medicinal chemistry 20071004 |
| Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome. | Current opinion in investigational drugs (London, England : 2000) 20070701 |
| Safinamide. | Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 20070101 |
| Safinamide: from molecular targets to a new anti-Parkinson drug. | Neurology 20061010 |
| Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition. | Neurology 20061010 |
| Bioassay of safinamide in biological fluids of humans and various animal species. | Arzneimittel-Forschung 20060101 |
| Improvement of motor function in early Parkinson disease by safinamide. | Neurology 20040824 |
| Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. | Pharmacological research 20040701 |
| Safinamide: FCE 26743, NW 1015, PNU 151774, PNU 151774E. | Drugs in R&D 20040101 |
| Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition. | Clinical neuropharmacology 20030101 |
| Safinamide (Newron Pharmaceuticals). | Current opinion in investigational drugs (London, England : 2000) 20010601 |